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Abstract
Background: The epidermal growth factor receptor (EGFR) is over expressed in approximately
50–60% of glioblastoma (GBM) tumors, and the most common EGFR mutant, EGFRvIII, is
expressed in 24–67% of cases. This study was designed to address whether over expressed EGFR
or EGFRvIII is an actual independent prognostic indicator of overall survival in a uniform body of
patients in whom gross total surgical resection (GTR; ≥ 95% resection) was not attempted or
achieved.
Methods: Biopsed or partially/subtotally resected GBM patients (N = 54) underwent adjuvant
conformal radiation and chemotherapy. Their EGFR and EGFRvIII status was determined by
immunohistochemistry and Kaplan-Meier estimates of overall survival were obtained.
Results: In our study of GBM patients with less than GTR, 42.6% (n = 23) failed to express EGFR,
25.9% (n = 14) had over expression of the wild-type EGFR only and 31.5 % (n = 17) expressed the
EGFRvIII. Patients within groups expressing the EGFR, EGFRvIII, or lacking EGFR expression did
not differ in age, Karnofsky Performance Scale (KPS) score, extent of tumor resection. They all had
received postoperative radiation and chemotherapy. The median overall survival times for patients
with tumors having no EGFR expression, over expressed EGFR only, or EGFRvIII were 12.3 (95%
CI, 8.04–16.56), 11.03 (95% CI, 10.18–11.89) and 14.07 (95% CI, 7.39–20.74) months, respectively,
log rank test p > 0.05). Patients with tumors that over expressed the EGFR and EGFRvIII were
more likely to present with ependymal spread, 21.4% and 35.3% respectively, compared to those
patients whose GBM failed to express either marker, 13.0%, although the difference was not
statistically significant. There was no significant difference in multifocal disease or gliomatosis
cerebri among EGFR expression groups.
Conclusion: The over expressed wild-type EGFR and EGFRvIII are not independent predictors of
median overall survival in the cohort of patients who did not undergo extensive tumor resection.
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Glioblastoma multiforme (GBM) is the most common
primary malignant neoplasm of the central nervous sys-
tem in adults. Despite multimodal therapies, the median
survival time of patients with GBM is approximately 1
year; however, there is considerable variability among
these patients. Prognostic indicators have included age
[1,2], Karnofsky Performance Scale (KPS) score [3], and
extent of surgical resection [4,5]. The most frequent
genetic alteration associated with GBM is amplification of
the epidermal growth factor receptor (EGFR) gene, which
results in over expression of the EGFR, a transmembrane
tyrosine kinase receptor [6]. The majority of GBMs with
EGFR amplification also contain the mutant EGFR gene,
EGFRvIII [7], which is characterized by the deletion of
exons 2–7, resulting in an in frame deletion variant that
has a truncated extracellular domain with ligand-inde-
pendent constitutive activity [8]. Previous work has
shown that EGFR amplification is evident in all GBMs
expressing EGFRvIII and GBMs lacking the amplified
EGFR are not positive for EGFRvIII protein. In addition,
we have previously shown that the positive staining with
the 528 antibody, which recognizes an unspecified extra-
cellular epitope of the EGFR, is highly correlated with
EGFR amplification [9].
The role of the over expressed EGFR (wild type) and the
variant (vIII) receptor in malignant progression of glial
tumors and their respective impacts on overall survival
have been debated in the literature. Over expression of
wild-type EGFR was not found to be an independent prog-
nostic indicator of survival in several studies [10-12], and
one study was inconclusive [13]. Four studies identified
EGFR as a negative prognostic indicator of survival [14-
16], one of which showed the effect only in patients
younger than 45 [17]. In some of these studies, analysis
was limited by small sample size, uncharacterized extent
of surgical resection, and variable postoperative treat-
ment. The prognostic impact of EGFRvIII has not been as
extensively studied, but in the study that addressed this
variable, the presence of EGFRvIII was found to be an
independent and significant unfavorable prognosticator
of survival [18]. In contrast, our group has shown that the
presence of the over expressed EGFR and EGFRvIII were
not independent negative prognostic indicators in
patients who were able to undergo gross total resection
(GTR)(>95% MRI-based volumetric resection) [19] when
confounding variables were accounted for. However, our
previous study had an inherent bias in that more invasive,
infiltrative tumors were less likely to be selected for sur-
gery and less likely to have a GTR. Thus, the primary pur-
pose of this study was to determine if EGFR and EGFRvIII
are negative prognostic indicators in patients who either
receive a biopsy, partial resection (<85%) or subtotal
resection (85–95%).
EGFR amplification and EGFRvIII have been shown to
increase glioma proliferation and invasion in vitro [8,9];
therefore logically EGFR and/or EGFRvIII expression
could exhibit a proclivity towards the development of
multifocal disease, gliomatosis cerebri or ependymal
seeding. Therefore, the secondary purpose of this study
was to address the natural history of EGFR and EGFRvIII
expression in GBM patients undergoing less than GTR.
Methods
Study Population
The study was conducted according to an IRB-approved
protocol (LAB03-0228). 54 GBM (WHO grade IV)
patients received conformal irradiation and adjuvant
chemotherapy and were retrospectively reviewed to deter-
mine whether tumor expression of EGFR or EGFRvIII con-
ferred a poor prognosis. Clinical and survival information
was obtained from the Department of Neurosurgery Clin-
ical and Imaging Database and The University of Texas M.
D. Anderson Cancer Center Tumor Registry. All tissue
specimens were acquired at initial diagnosis and resection
and were classified morphologically and graded according
to WHO criteria.
Immunohistochemical Detection of Over Expressed EGFR 
and EGFRvIII
Immunostaining was performed as previously described
[17]. Briefly, 5-µm tumor-tissue sections were mounted
on positively charged slides, deparaffinized, and rehy-
drated in phosphate-buffered saline (PBS). Endogenous
peroxidase activity was blocked with 3% hydrogen perox-
ide in PBS/0.05% Tween 20 for 20 min. Sections were
washed in PBS and blocked for 20 min in the appropriate
serum (from the same species as the secondary antibody)
diluted to 10% in PBS. The primary antibody for EGFR
detection was the monoclonal mouse anti-human pan-
EGFR clone 528 (Oncogene Research; 1:50 dilution) [20]
and for EGFRvIII detection was a rabbit anti-human poly-
clonal antibody (Zymed, San Francisco, CA; 1:1200 dilu-
tion). For EGFRvIII staining, microwave antigen retrieval
was performed by placing the slides in 50 mM citrate
buffer (pH 6.0) and microwaving for 12 min at full power
and 10 min at 20% power, followed by cooling for 15 min
and two to three 5-min washes in PBS. For EGFR staining,
pretreatment consisted of placing 0.025% trypsin on the
tissue and incubating for 30 min at room temperature.
Primary antibodies, diluted in PBS/10% serum, were
applied to the sections in a humid chamber overnight at
4°C. Sections were washed two to three times in PBS, and
secondary antibodies were applied using the Dako
(Carpinteria, CA) Envision kit, according to the manufac-
turer's instructions. Detection of bound secondary anti-
body was performed with diaminobenzadine for 5 min.
Sections were then counterstained with hematoxylin and
mounted. Each batch of stained slides was accompaniedPage 2 of 6
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staining for EGFR and EGFRvIII), as well as demonstra-
tion of gene amplification using samples previously
described as positive by both genetic analyses (Southern
analysis and RT-PCR) as well as immunohistochemistry
[9]. Non-neoplastic brain tissue was used as a negative
control, and positive staining was never seen in this tissue.
As additional controls, 20 randomly selected cases were
stained using equal concentrations of mouse (anti-cytok-
eratin 14, Biogenex, San Ramon, CA) and rabbit antibod-
ies (anti-cytokeratin 19, Neomarkers of Lab Vision
Corporation, Fremont, CA) at concentrations matching
the EGFR and EGFRvIII staining conditions, respectively.
These irrelevant controls were uniformly negative in each
of the 20 cases tested. Scoring was accomplished using a
simple positive-negative scoring system. Any detectable
cytoplasmic-membrane staining in tumor cells was scored
as positive/overexpressed.
Statistical Analysis
The frequencies and descriptive statistics of demographic
and clinical variables were performed for the patients in
this study. The chi-square or exact test (StatXact 3 for Win-
dows) was used for categorical variables as appropriate.
The analysis of variance was used for continuous varia-
bles. Cumulative survival times from the time of surgery
at our institution were computed using the Kaplan-Meier
method [21]. Overall survival curves for the various sub-
groups were compared using the log rank test. The Cox
proportional hazards model was used to obtain crude rate
ratios, adjusted rate ratios and their 95% confidence inter-
vals for the various EGFR categories [22]. Adjustments
were done for age, sex, KPS score, radiographic enhance-
ment, radiographic necrosis, extent of edema, midline




In our study of 54 GBM patients, 43% (n = 23) failed to
express the EGFR, 57% (n = 31) were positive for the pan-
EGFR stain and of those that expressed EGFR, 31% (n =
17) also expressed the EGFRvIII variant while 26% (n =
14) failed to express EGFRvIII. Staining for EGFR was typ-
ically diffuse, while the staining for EGFR vIII was gener-
ally more focal (not shown) as has been previously
reported [23]. This distribution of expression was similar
to those GBM patients who underwent GTR [19]. There
was no significant difference in age, KPS score, or extent of
surgical resection (biopsy, subtotal or partial resection)
among the patients whose tumors failed to express EGFR,
over expressed the wild-type EGFR, or expressed EGFRvIII
(Table 1). Interestingly, men were more likely to over
express EGFR only (79%) or EGFRvIII (88%). This was
Table 1: Demographic characteristics of patients with glioblastoma multiforme categorized according to epidermal growth factor 
receptor expression of the tumor
Parameter EGFRa negative EGFRwt positive only EGFRvIII positive
Total 54, N (%) 23 (43) 14 (26) 17 (31)
*Sex, N (%) M 15 (65) 11 (79) 15 (88)
F 8 (35) 3 (21) 2 (22)
*Age, years, Median (range) 57 (15–79) 65 (25–71) 59 (54–73)
*KPS score, Median (range) 90 (50–100) 80 (50–90) 90 (60–100)
aEGFR, epidermal growth factor receptor; wt, wild type; vIII, vIII mutant; KPS, Karnofsky Performance Scale.
Table 2: Radiographic characteristics and post surgical events in glioblastomas according to epidermal growth factor receptor 
expression category
Parameter EGFRa negative EGFRwt positive EGFRvIII positive
Total of 54, N (%) 23 (43) 14 (26) 17 (31)
Cortical matter involvement, N (%)
Yes 17 (74) 10 (71) 11 (65)
No 6 (26) 4 (29) 6 (35)
Ependymal, N (%) yes 3 (13) 3 (21) 6 (35)
Multifocality, N (%) Yes 2 (9) 2 (14) 2 (12)
Gliomatosis cerebri, N (%) Yes 5 (22) 4 (29) 3 (18)
*Severe necrosis (grade 3), N (%) Yes 5 (24) 6 (46) 7 (44)
aEGFR, epidermal growth factor receptor; wt, wild type; vIII, vIII mutant; *radiographic imaging not available for all patients.Page 3 of 6
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GTRs [19].
While there was a trend towards increased post-surgical
incidence of pulmonary embolus in patients who
expressed the EGFRvIII (17.6%) compared to those who
over expressed the EGFR only (7.1%) or failed to express
EGFR (8.7%), it was not statistically significant (p = 0.36).
No such trend was observed with DVT.
Radiographic Characteristics
There was no significant difference in the location, extent
of necrosis, amount of MR image contrast-enhancement,
extent of edema, or amount of brain midline shift among
the three EGFR expression categories of GBMs (Table 2).
There was no significant difference in the ratio of MRI T2-
bright volume to T1-enhancing volume between EGFR
expression groups.
Natural Disease History Based on EGFR and EGFRvIII 
Expression in GBMs
Patients that over expressed the EGFR or expressed the
EGFRvIII presented with a greater incidence of ependymal
spread, 21.4% and 35.3% respectively, when compared to
tumors that failed to express either marker 13.0% but this
was not statistically significant. Ependymal spread nega-
tively impacted median survival in EGFR expressing (5.3
versus 11. months) and EGFRvIII expressing (8.3 versus
15 months) GBM patients. There were no significant dif-
ferences in the percentages of patients who had multifocal
disease or gliomatosis cerebri, irrespective of EGFR or
EGFRvIII expression status. However, there was an 18–
22% incidence of gliomatosis cerebri in all EGFR expres-
sion categories in the less than GTR patient group com-
pared to only 3–5% incidence in those patient who
underwent GTR.
Impact of EGFR or EGFRvIII on Survival
Over expressed wild-type EGFR or EGFRvIII were not
independent predictors of overall survival and did not
confer a worse prognosis (Figure 1). The median overall
survival times for patients with tumors having no EGFR
expression, over expressed EGFR only, or EGFRvIII were
12.3 (95% CI, 8.04–16.56), 11.03 (95% CI, 10.18–11.89)
and 14.07 (95% CI, 7.39–20.74) months, respectively,
indicating that neither EGFR or EGFRvIII were negative
prognostic indicators in GBM patients unable to undergo
GTR. The median overall survival times for patients who
underwent GTR with tumors having no EGFR expression,
over expressed EGFR only, or mutant EGFRvIII was 11.68,
11.9 and 13.0 months, respectively indicating that the
median survival were not significantly different from
those patients who underwent GTR. Our group has previ-
ously demonstrated that the extent of surgical resection
impacts survival in a series of 416 patients with glioblast-
oma multiforme [4]. The statistically significant impact
on survival started in those patients who received 89%
volumetric resections or greater. The vast majority of
patients in our current study were subtotal resections
defined as extents of resection of 85% to <95%, as
opposed to <85%. This could account for the comparable
survival to the GTR cohort (≥ 95% resection). There was
no significant difference in age or KPS between patients
who underwent GTR and those who did not.
Established Prognostic Factors
Our results were consistent with prior findings demon-
strating that age ≥ 65 years has a negative prognostic
impact on survival although this difference did not reach
statistical significance, p = 0.33). This was likely due to
our small sample size and a paucity of young and very old
patients (n = 4 under 40 years; n = 2 over 75 years). KPS
score was found to be an independent prognostic indica-
tor in our study, consistent with previous studies that have
validated KPS as a prognostic indicator in GBM patients.
Radiographically visualized necrosis was more common
in EGFR-expressing tumors but the sample size was insuf-
ficient to ascertain if necrosis was a negative prognostica-
tor.
Graph showing Kaplan-Meier estimates of overall survival in glioblastoma multiforme patients who underwent b-total resection followed by standa d-of-c r  ra iation he apy nd chemot erapyF gure 1
Graph showing Kaplan-Meier estimates of overall 
survival in glioblastoma multiforme patients who 
underwent sub-total resection followed by standard-
of-care radiation therapy and chemotherapy. Patients 
with tumors not expressing the epidermal growth factor 
receptor (EGFR; n = 23; solid black line), expressing ampli-
fied EGFR (n = 14; dashed grey line), and expressing EGFRvIII 
(n = 17; dotted black line) had median overall survival times 
of 12.3 (95% CI, 8.04–16.56), 11.03 (95% CI, 10.18–11.89), 
and 14.07 (95% CI, 7.39–20.74) months, respectively, which 
were not statistically significantly different.
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Despite previous reports indicating that EGFR and
EGFRvIII were negative prognostic indicators, we found
that neither the over expressed wild-type EGFR nor
EGFRvIII were independent predictors of median overall
survival in GBM patients who underwent GTR (≥ 95% vol-
umetric resection). The median overall survival times for
patients who had tumors devoid of EGFR expression, with
over expression of EGFR, or with mutant (EGFRvIII)
expression were 0.96, 0.98, and 1.07 years, respectively. In
the study by Shinojima et al. [18], the authors concluded
that EGFR amplification in GBMs was associated with
shorter patient survival in a heterogeneous group of
patients who underwent a wide variety of treatments
including gross-total resection, partial resection, and
biopsy. We therefore hypothesized that the EGFR and
EGFRvIII may have a negative prognostic impact in
patients that are not able to undergo GTR. This would be
one potential variable to account for the discrepancies
between the results. However, we did not see a difference
in median survival across EGFR expression categories in
the subcategory of patients unable to undergo GTR.
As others have found there was a range in the positive
cases with respect to the proportion of tumor cells which
were positive. This was especially true for EGFRvIII [23].
The number of samples in this study was relatively small
given the restriction to subtotally resected cases, and
therefore stratification by proportion of positively stained
cells was not attempted. However, future studies examin-
ing this issue in EGFRvIII-positive tumors are warranted.
We investigated the possibility that the absence of an
EGFR prognostic effect could be explained by the age dis-
tribution of our sample. Simmons et al. [17] had demon-
strated that EGFR over expression was an unfavorable
prognostic factor in patients less than 55 years of age. In
the study by Shinojima et al. [18], 97% of the patients
were <70 years old. If EGFR over expression is truly an
unfavorable prognostic factor in younger age patients,
such an age distribution may have been sufficient to influ-
ence the authors' conclusion that EGFR over expression
impacted survival rates independently of age. In our
study, however, the respective median overall survival
times for our patients under 55 years of age whose tumors
expressed neither type of EGFR, overexpressed wild type
EGFR or expressed EGFRvIII, were not statistically differ-
ent. In our earlier study of patients who underwent GTR
we saw a trend toward a negative effect of EGFR and
EGFRvIII expression on survival in patients under 40 years
of age. However, no conclusion could be drawn for this
subgroup in this study as there were only 4 patients aged
<40. Though age bias is an unlikely explanation for the
negative findings in our study, the differential effect of
EGFR within different age groups requires further investi-
gation.
EGFR and EGFRvIII expression have been shown to
increase the infiltrative and invasive properties of glioma
cells [24,25], therefore, one could hypothesize that
patients expressing these markers may be more likely to
present with multifocal disease, ependymal dissemina-
tion, or gliomatosis cerebri and perhaps this is the con-
founding variable between the studies accounting for the
discrepancy in prognostic impact. GTR is not possible
when there is multifocal disease, extensive ependymal
spread or gliomatosis cerebri. Patients deemed "unresect-
able" due to extensive tumor invasion and multifocality of
disease may have been more likely to have the over
expression of the EGFR or the EGFRvIII. Additionally,
these characteristics on radiographic presentation typi-
cally influence the treatment options toward biopsy and
palliative treatment modalities. Although there was a
trend of increased ependymal involvement within tumors
expressing EGFR (21%) and EGFRvIII (35%) compared
with tumors not expressing EGFR (13%) in patients not
undergoing GTR, this was not statistically significant. The
study sample was too small to determine if there was a sta-
tistically significant difference in the incidence of glioma-
tosis cerebri or multifocal disease. We did observe an
increased incidence of gliomatosis cerebri in GBM
patients that did not undergo GTR compared to those that
were able to undergo GTR. These factors were not
addressed in the other studies and could potentially
account for the differences in EGFR and EGFRvIII prog-
nostic impact between these studies, especially if there
was a significant incidence of these in a small series. Alter-
natively, there may be unidentified confounding variable
that our studies and the other published ones did not
account for.
Conclusion
Within the subcategory of patients with GBM who under-
went less than GTR, the presence of EGFR or EGFRvIII as
a single mutation does not account for poor prognosis;
however, simultaneous molecular genetic changes with
prognostic significance have not been addressed in this
study.
Declaration of competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
ABH conceived the project, designed and coordinated the
study and drafted the manuscript. DS designed the data-
base and carried out the data analysis. DY participated in
the database design and assisted with the immunohisto-
chemistry. WS performed the detailed volumetric andPage 5 of 6
(page number not for citation purposes)
Journal of Translational Medicine 2005, 3:38 http://www.translational-medicine.com/content/3/1/38Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
radiographic analysis. KA performed and interpreted the
immunohistochemistry. All authors read and approved
the final manuscript.
Acknowledgements
We thank Betty L. Notzon for their editorial assistance in preparation of 
this manuscript and Dr. Jeff Weinberg for constructive criticisms. The data 
contained within this manuscript was presented at the 13th World Con-
gress of Neurological Surgeons, Marrakesh, Morocco, June 2005. This work 
was supported by The University of Texas M. D. Anderson Cancer Center 
Department of Neurosurgery recruitment start-up funds to ABH.
References
1. Kallio M, Sankila R, Jaaskelainen J, Karjalainen S, Hakulinen T: A pop-
ulation-based study on the incidence and survival rates of 3857 glioma
patients diagnosed from 1953 to 1984.  Cancer 1991, 68:1394-1400.
2. Davis FG, Freels S, Grutsch J, Barlas S, Brem S: Survival rates in
patients with primary malignant brain tumors stratified by
patient age and tumor histological type: an analysis based on
Surveillance, Epidemiology, and End Results (SEER) data,
1973-1991.  J Neurosurg 1998, 88:1-10.
3. Curran WJJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach
AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al.: Recursive
partitioning analysis of prognostic factors in three Radiation
Therapy Oncology Group malignant glioma trials.  J Natl Can-
cer Inst 1993, 85:704-710.
4. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F,
Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael
C, Miller D, Sawaya R: A multivariate analysis of 416 patients
with glioblastoma multiforme: prognosis, extent of resec-
tion, and survival.  J Neurosurg 2001, 95:190-198.
5. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial ana-
plastic gliomas in adults. The prognostic importance of
extent of resection and prior low-grade glioma.  J Neurosurg
1989, 71:487-493.
6. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Col-
lins VP: Genes for epidermal growth factor receptor, trans-
forming growth factor alpha, and epidermal growth factor
and their expression in human gliomas in vivo.  Cancer Res
1991, 51:2164-2172.
7. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD: Cell surface
localization and density of the tumor-associated variant of
the epidermal growth factor receptor, EGFRvIII.  Cancer Res
1997, 57:4130-4140.
8. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James
CD: Functional characterization of an EGF receptor with a
truncated extracellular domain expressed in glioblastomas
with EGFR gene amplification.  Oncogene 1994, 9:2313-2320.
9. Aldape KD, Ballman K, Furth A, Buchner JC, Giannini C, Burger PC,
Scheithauer BW, Jenkins RB, James CD: Immunohistochemical
detection of EGFRvIII in high malignancy grade astrocyto-
mas and evaluation of prognostic significance.  J Neuropathol
Exp Neurol 2004, 63:700-707.
10. Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J,
Wang CH, Scheithauer BW, James CD: Gene amplification as a
prognostic factor in primary and secondary high-grade
malignant gliomas.  Int J Oncol 1998, 13:717-724.
11. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller
DC: Survival of patients with glioblastoma multiforme is not
influenced by altered expression of p16, p53, EGFR, MDM2
or Bcl-2 genes.  Brain Pathol 1998, 8:655-667.
12. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann
D, Astrahantseff K, Blumcke I, von Deimling A, Schlegel U: Lack of
prognostic relevance of alterations in the epidermal growth
factor receptor-transforming growth factor-alpha pathway
in human astrocytic gliomas.  J Neurosurg 1996, 85:634-641.
13. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Fig-
arella-Branger D: Prognostic significance of Ki67, p53 and epi-
dermal growth factor receptor immunostaining in human
glioblastomas.  Neuropathol Appl Neurobiol 1998, 24:381-388.
14. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM: Epidermal growth
factor receptor: an independent predictor of survival in
astrocytic tumors given definitive irradiation.  Int J Radiat Oncol
Biol Phys 1996, 34:809-815.
15. Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M,
Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M,
Grellier P, Frenay M, Milano G: Epidermal growth factor recep-
tor and labeling index are independent prognostic factors in
glial tumor outcome.  Clin Cancer Res 1998, 4:2383-2390.
16. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N,
O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC,
Jenkins RB: PTEN mutation, EGFR amplification, and out-
come in patients with anaplastic astrocytoma and glioblast-
oma multiforme.  J Natl Cancer Inst 2001, 93:1246-1256.
17. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger
MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG, Aldape K:
Analysis of complex relationships between age, p53, epider-
mal growth factor receptor, and survival in glioblastoma
patients.  Cancer Research 2001, 61:1122-1128.
18. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H,
Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y:
Prognostic value of epidermal growth factor receptor in
patients with glioblastoma multiforme.  Cancer Res 2003,
63:6962-6970.
19. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M,
Sawaya R, Aldape K: Prognostic effect of epidermal growth fac-
tor receptor and EGFRvIII in glioblastoma multiforme
patients.  Clin Cancer Res 2005, 11:1462-1466.
20. Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Will-
ingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR:
Tumor-specific anti-epidermal growth factor receptor vari-
ant III monoclonal antibodies: use of the tyramine-cellobiose
radioiodination method enhances cellular retention and
uptake in tumor xenografts.  Cancer Res 1995, 55:4375-4382.
21. Kaplan EL, Meier P: Nonparametric estimation from incom-
plete observations.  J Am Stat Assoc 1958, 53:457-481.
22. Cox DR: Regression models and life-tables.  J R Stat Soc 1972,
34:187-220.
23. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H: Predominant
expression of mutant EGFR (EGFRvIII) is rare in primary
glioblastomas.  Brain Pathol 2004, 14:131-136.
24. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD,
Laerum OD: Effect of epidermal growth factor on glioma cell
growth, migration, and invasion in vitro.  Cancer Res 1990,
50:6039-6044.
25. Tysnes BB, Haugland HK, Bjerkvig R: Epidermal growth factor
and laminin receptors contribute to migratory and invasive
properties of gliomas.  Invasion Metastasis 1997, 17:270-280.Page 6 of 6
(page number not for citation purposes)
